research Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Treatments for PCOS aim to reduce androgen levels and improve insulin sensitivity to lower cardiometabolic risk.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Bimatoprost
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Experimental Assessment of 3-<i>meta</i>-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors <i>in silico</i> and <i>in vivo</i> Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Modulation of the 6-position of benzopyran derivatives and inhibitory effects on the insulin releasing process
Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
research The role of correction of metabolic disorders in the treatment of androgenetic alopecia in women
Using a combined treatment of minoxidil and metformin can improve hair loss in women by normalizing hormone and metabolism levels.
research 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
research Identification of key genes in type 2 diabetes‐induced erectile dysfunction rats with stem cell therapy through high‐throughput sequencing and bioinformatic analysis
Stem cell therapy affects 15 key genes in rats with diabetes-related erectile dysfunction.
research Finasteride Reduces Microvessel Density and Expression of Vascular Endothelial Growth Factor in Renal Tissue of Diabetic Rats
Finasteride helps reduce blood vessel growth in diabetic rat kidneys.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells
Troxerutin helps protect skin cells from oxidative stress and may be good for treating hair loss.
research Evaluation of the palatal wound healing effect of wound dressing carrying GSK-3 antagonist tideglusib on rats
Tideglusib with hydrogel improves wound healing in rats.
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research Synergistic therapeutic effect of ginsenoside Rg3 modified minoxidil transfersomes (MXD-Rg3@TFs) on androgenic alopecia in C57BL/6 mice
Ginsenoside Rg3 combined with minoxidil was more effective in treating hair loss in mice.
research Chronic Exposure with 5‐Alpha Reductase Inhibitor Ameliorates Anxiety and Depression‐like Behaviors By Reducing Systemic Oxidative Stress in D‐galactose‐Induced Aging Male Rats
Finasteride may help reduce anxiety and depression in elderly but might cause depression in young men.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim
Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
research Major Improvement in Wound Healing Through Pharmacologic Mobilization of Stem Cells in Severely Diabetic Rats
A new therapy sped up wound healing and reduced scarring in diabetic rats.
research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
research Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
research Diabetex: A novel approach for diabetic wound healing
Diabetex improves diabetic wound healing better than metformin.
research Glycolytic Dysfunction in Granulosa Cells and Its Contribution to Metabolic Dysfunction in Polycystic Ovary Syndrome
Targeting glycolysis may help treat PCOS by improving insulin sensitivity and ovarian function.
research Mechanistic Underlying Anti-diabetic Potential of Eclipta alba Flavonoids against Aldose Reductase Inhibitory Action
Eclipta alba flavonoids may help treat diabetes by effectively inhibiting Aldose reductase.
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.